A teal gland-like silhouette beside a folded ribbon and rounded signal forms.

Our evidence assessments are specific to an outcome, population, and formulation.

Read our grading method

CJC-1295

Hormone-marker findings and the gap to meaningful health outcomes.

Hormones
Written by

Recorded source check: 3 October 2026

Review and updates

Overview

CJC-1295 is an analogue of growth hormone–releasing hormone; the long-acting formulation studied in human trials increased growth hormone and insulin-like growth factor 1 (IGF-1).[1] The human findings summarized here primarily concern hormone concentrations and the behavior of the studied preparation over time.[1] Those measurements do not themselves demonstrate better sleep, muscle performance, fat loss, or injury recovery, and differently specified products need separate assessment.[1] The guide explains the importance of the long-acting formulation, distinguishes single-agent studies from combination claims, and sets out the safety and dosing questions that remain unresolved for other uses.

Benefits

CJC-1295 has demonstrated hormonal activity in humans, but that does not establish improved recovery or muscle performance.[1] Two short randomized, placebo-controlled trials of the long-acting formulation found increases in growth hormone and IGF-1 in healthy adults.[1] These were pharmacology studies, not demonstrations of faster injury healing, greater strength, better sleep, or longer life.[1] A biomarker response is useful for understanding what a compound does, while meaningful benefit requires direct clinical outcomes.[1] Results from the studied long-acting molecule should also not be automatically assigned to products marketed as CJC-1295 without DAC or to combination products.[1]

Safety

FDA identifies increased heart rate and systemic vasodilatory reactions among serious events associated with CJC-1295, while emphasizing the limited clinical data.[2] Its 2024 assessment also describes injection-site reactions, headache, flushing, dizziness and low blood pressure in early studies; the long-term safety profile remains unknown.[3] Interpret these observations alongside the study population, route, and length of follow-up. A report of an event does not by itself establish causation, while a study that reports few events cannot exclude uncommon or delayed harms.

Contraindications

The cited trials enrolled healthy adults aged 21–61; that study population does not establish a complete contraindication list or suitability for people with medical conditions.[1] FDA found no data informing pediatric safety and identified gaps in reproductive and long-term safety research, so these populations cannot be assumed safe on the basis of the adult trials.[3] Eligibility criteria show whom researchers chose to study; they are not a complete assessment of who can safely receive a product. Any conclusion about suitability therefore needs the exact formulation, the person’s health history, and evidence that actually addresses the relevant circumstances.

Interactions

Separate human experiments found that CJC-1295 increased GH and IGF-1 and that ipamorelin stimulated GH, but these cited experiments did not test the combination.[1][4] Our interpretation is that these hormone-response findings cannot establish the safety or added clinical benefit of combining the two.[1][4] To evaluate an interaction, the evidence needs to address the substances together and describe the outcome being monitored. Separate studies cannot establish the combined effect, and an unanswered interaction question should remain an uncertainty rather than becoming reassurance.

Forms & dosing

FDA distinguishes CJC-1295 substances with and without a drug affinity complex (DAC), and notes that published clinical references appear to involve DAC-containing material without specifying its salt form.[3] Consequently, the long-acting trial cannot establish an interchangeable dosing schedule for products labeled without DAC.[1][3] The amount administered is only one part of an intervention: formulation, route, frequency, treatment duration, and monitoring also define what was tested. Keeping those details attached to a result prevents a research schedule from being presented as a validated regimen for a different use.

Results & stopping

In the early trials, the estimated half-life was 5.8–8.1 days, and mean IGF-1 remained above baseline for up to 28 days after repeated administration.[1] These measurements describe drug exposure and hormone responses; they do not establish durable improvements in recovery or body composition after treatment ends.[1] Time to a measured response and persistence after treatment ends are separate questions. A meaningful interpretation needs to specify the outcome, when it was assessed, and whether follow-up actually continued after treatment stopped, rather than infer lasting benefit from an early response.

Product quality

FDA found that certificates it reviewed for CJC-1295 DAC free base often reported purity without an impurity profile, and concluded that this material was not well characterized.[3] FDA separately warns that contamination or incorrect active-ingredient amounts in compounded drugs can cause serious harm, so a purity percentage alone cannot establish finished-product safety.[5] A useful quality assessment needs to connect the tested sample to the actual product and explain what the test can establish. Evidence about identity or composition should remain distinct from evidence that the finished product is effective, suitable for a particular route, or clinically safe.

Status

At the October 3, 2026 check, FDA listed CJC-1295 among withdrawn compounding nominations while retaining its safety warning.[2] That compounding entry is not a drug approval: FDA states that compounded drugs are not FDA-approved and undergo no premarket agency review for safety, effectiveness or quality.[5] Regulatory status needs to be read for the exact substance, finished product, indication, and jurisdiction being discussed. A research publication, a supplier listing, and a regulatory decision answer different questions, so none should be used as a substitute for the others.

Evidence

These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.

Selected findings and their main limitations. Open an outcome or source count for the complete assessment. Counts refer to cited documents, not necessarily independent studies.
Outcome, finding and study designEvidence certaintySources
Human researchRandomized pharmacology trials; indirect for clinical benefit.[1]

CJC-1295 has demonstrated hormonal activity in humans, but that does not establish improved recovery or muscle performance.[1] Two short randomized, placebo-controlled trials of the long-acting formulation found increases in growth hormone and IGF-1 in healthy adults.[1] These were pharmacology studies, not demonstrations of faster injury healing, greater strength, better sleep, or longer life.[1]

Main limitation: GH and IGF-1 are surrogate outcomes for the proposed benefits.[1]

Research Feed

Studies

Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.

PDF recordNeuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth
PDF recordProbing for peptidic drugs (2–10 kDa) in doping control blood samples
PDF recordQualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS

FAQs

Does raising growth hormone with CJC-1295 prove better recovery or muscle growth?
Quick answer:

CJC-1295 has demonstrated hormonal activity in humans, but that does not establish improved recovery or muscle performance.[1] Two short randomized, placebo-controlled trials of the long-acting formulation found increases in growth hormone and IGF-1 in healthy adults.[1] These were pharmacology studies, not demonstrations of faster injury healing, greater strength, better sleep, or longer life.[1] A biomarker response is useful for understanding what a compound does, while meaningful benefit requires direct clinical outcomes.[1] Results from the studied long-acting molecule should also not be automatically assigned to products marketed as CJC-1295 without DAC or to combination products.[1]

Update History

Evidence and review status

Recorded source check
Subsequent substantive evidence update
No later update is recorded for CJC-1295.
Independent clinical review
Pending; this selected-source guide is AI-assisted.

A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.

Read the editorial method

References

7 sources
  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (2006)Primary researchReview status · PendingSave study
  2. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Accessed 2026-10-03)Regulatory guidanceSave study
  3. December 4, 2024 Pharmacy Compounding Advisory Committee Meeting: FDA presentation on CJC-1295 (2024)Regulatory assessmentSave study
  4. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (1999)Human pharmacology studyReview status · PendingSave study
  5. Understanding the Risks of Compounded Drugs (Accessed 2026-10-03)Regulatory guidanceSave study
  6. Discussionr/PeptidesCJC 1295 no Dac with Ipamorelin for sleep
  7. Discussionr/RealSteroidWikiDo GH Secretagogues Affect Blood Sugar?

Selected public discussions help us choose questions. They are not clinical evidence. Explore discussions